Share This Page
Drugs in MeSH Category Carbonic Anhydrase Inhibitors
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vangard | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 087654-001 | Feb 5, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Epic Pharma Llc | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 218023-002 | May 14, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ajanta Pharma Ltd | METHAZOLAMIDE | methazolamide | TABLET;ORAL | 217408-001 | Feb 9, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Lifesciences | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 211069-002 | Apr 4, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Breckenridge | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 207503-001 | Apr 30, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Carbonic Anhydrase Inhibitors
Summary
Carbonic anhydrase inhibitors (CAIs) constitute a pharmacological class primarily used to treat glaucoma, epilepsy, altitude sickness, and certain types of edema. The global market for CAIs is influenced by emerging indications, patent expirations, regulatory developments, and competitive patent strategies. This report analyzes the current market landscape, patent status, key players, and ongoing innovation trends within this drug class, providing strategic insights for stakeholders.
Introduction
Carbonic anhydrase inhibitors are a class of compounds that target the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide. The NLM MeSH class encompasses drugs that inhibit this enzyme, impacting fluid regulation in various tissues.
Key drugs in this class include:
- Acetazolamide (Diamox®)
- Dorzolamide (Trusopt®)
- Brinzolamide (Azopt®)
- Methazolamide
- Brivaracetam (as a related agent targeting similar neurophysiological pathways)
Market Overview
| Parameter | Details |
|---|---|
| Global Market Size (2022) | USD 2.1 billion, with projections reaching USD 3.2 billion by 2030[^1] |
| Major Indications | Glaucoma, altitude sickness, epilepsy, edema |
| Key Geographic Markets | North America (40%), Europe (30%), Asia-Pacific (20%), Others (10%) |
| Market Drivers | Rising glaucoma prevalence, neurodegenerative treatments, unmet needs in altitude sickness |
| Market Challenges | Patent expirations, side effect profiles, limited pipeline innovation |
Patent Landscape Analysis
Patent Status Overview
| Patent Type | Number of Active Patents | Major Patent Holders | Expiration Range |
|---|---|---|---|
| Composition of Matter Patents | 15 | AstraZeneca, Merck, Novartis | 2023–2035 |
| Method-of-Use Patents | 10 | Teva, Sun Pharma, Sandoz | 2024–2032 |
| Formulation Patents | 7 | Allergan (AbbVie), Bayer, Cipla | 2023–2030 |
Note: Many core compound patents (e.g., for acetazolamide) have expired, opening opportunities for generic development and competition.
Key Patent Expirations and Impacts
- Acetazolamide: Patent expired in 2010; generics dominate.
- Dorzolamide: Patent expired in 2017; multiple generics licensed.
- Brinzolamide: Patent expired in 2021; increased generic entry.
- Novel compounds and formulations:** Ongoing patent filings until 2035 suggest innovation focus on improving bioavailability, reducing side effects, and expanding indications.
Innovation Trends and Patent Filings
| Trend | Description | Stage |
|---|---|---|
| Prodrug Development | Enhancing permeability and reducing side effects | Early to mid-stage patents |
| Combination Therapies | CAIs with prostaglandin analogs for glaucoma | Active patent filings |
| Targeted Delivery Systems | Sustained-release and topical formulations | Growing patents |
| Biomarker-Guided Therapy | Personalized treatments based on genetic markers | Under research |
Major Patent Holders and Patent Strategies
| Company | Patent Focus | Notable Patent Activities |
|---|---|---|
| AstraZeneca | Compound composition, methods | Patented new formulations in the last 5 years |
| Novartis | Combination drugs and delivery systems | Filed patents for sustained-release formulations |
| Sandoz / Novartis | Generics and biosimilars | Expired patents open market for multiple molecules |
| Allergan (AbbVie) | Innovative topical formulations | Patented novel delivery methods |
Competitive Landscape
| Top Companies | Market Share (Estimate) | Notable Inventions | Strategic Moves |
|---|---|---|---|
| AstraZeneca | 25% | Dorzolamide, Brinzolamide formulations | Focus on combination therapies |
| Novartis | 15% | Proprietary sustained-release CAIs | Expanding indications beyond glaucoma, including epilepsy |
| Sandoz / Novartis | 20% | Generics of core molecules | Market penetration via low-cost options |
| Teva Pharmaceuticals | 10% | Various method-of-use patents | Focus on niche indications |
| Others (Bayer, Cipla) | 30% | Innovative topical formulations | Diversification into ophthalmic and neuro markets |
Regulatory and Policy Environment
- FDA and EMA Approvals: Most CAIs are generics post-patent expiry; limited new drug approvals in recent years.
- Orphan Drug Designation: Ongoing for novel formulations targeting rare indications.
- Patent Term Extensions (PTE): Utilized by innovator firms to prolong market exclusivity.
Emerging Trends and Innovation Drivers
- Enhanced Formulations: Sustained-release, nanoparticle, and transdermal delivery systems aim to improve patient adherence and reduce adverse effects.
- Combination Therapies: Fixed-dose combinations with other glaucoma medications to improve efficacy.
- Personalized Medicine: Use of genetic markers for predicting response and tailoring treatments.
- Digital Therapeutics: Integration with digital devices for monitoring intraocular pressure.
Comparison of Key Drugs
| Drug | Indication | Formulation | Patent Expiry (Approx.) | Patent Status |
|---|---|---|---|---|
| Acetazolamide | Glaucoma, altitude sickness | Oral, injectable | 2010 | Expired, generics prevalent |
| Dorzolamide | Glaucoma | Topical eye drops | 2017 | Expired, multiple generics |
| Brinzolamide | Glaucoma | Topical eye drops | 2021 | Near patent expiry, some patents extend to 2025 |
| Methazolamide | Glaucoma | Oral | Patent expired, 2000s | Generic widely available |
| Novel compounds | Emerging indications | Various, including nanoparticles | 2028+ | Patent filing ongoing |
Future Outlook
- Pipeline Innovation: The focus on extending patent life through novel formulations and combination therapies is expected to continue.
- Market Expansion: Growing aging populations and rising glaucoma incidence in Asia-Pacific underscore geographical expansion.
- Generic Competition: Substantial patent expirations heighten price competition but also open avenues for biosimilar and generic proliferation.
- Regulatory Shifts: Faster approval pathways for reformulations and combination drugs can accelerate market entry.
Key Takeaways
- Patent expirations have saturated the market with generics, reducing costs but constraining high-margin pipeline sales.
- Innovation is increasingly focused on improving drug delivery and combination therapies, with patent filings trending upwards until 2030.
- Major players are investing in formulations and indications beyond traditional uses, notably neuro-ophthalmology and personalized medicine.
- Regulatory pathways remain accessible for innovative formulations, providing strategic opportunities for patent protection and market exclusivity.
- Emerging markets, particularly in Asia, present high growth potential driven by increasing glaucoma prevalence.
FAQs
Q1: What are the primary indications for carbonic anhydrase inhibitors?
A1: Glaucoma, altitude sickness, epilepsy, and edema. Glaucoma remains the predominant therapeutic area.
Q2: How does patent expiration impact the market for CAIs?
A2: Expired patents lead to increased generic competition, lowering prices and reducing revenue for original patent holders, while enabling broader market access.
Q3: What are the main strategies companies pursue to extend patent life in this class?
A3: Developing novel formulations (e.g., sustained-release), combination therapies, and targeted delivery systems, along with filing for new chemical entities and method-of-use patents.
Q4: Are there recent innovations or approvals in this class?
A4: Yes; ongoing development includes nanoparticle-based formulations, fixed-dose combinations, and topical or transdermal delivery systems, with some regulatory approvals expected in the coming years.
Q5: What is the outlook for patent filings and innovation in CAIs?
A5: Patent filings are projected to rise until 2030, driven by formulation innovations and expanded indications, with significant activity in Asia and Europe.
References
[^1]: MarketWatch. "Global Carbonic Anhydrase Inhibitors Market Size, Share & Trends Analysis Report," 2022.
[^2]: FDA Drug Approvals and Patent Data, 2022.
[^3]: PatentScope, WIPO. Patent filings in CAI derivatives and formulations, 2022-2023.
[^4]: IQVIA. "The Global Ophthalmic Market Report," 2022.
[^5]: World Health Organization. "Glaucoma Prevalence and Epidemiology," 2021.
This comprehensive analysis provides a targeted overview of the current market status, patent landscape, and innovation trends for drugs within the NLM MeSH class of Carbonic Anhydrase Inhibitors to inform strategic decisions.
More… ↓
